3US Department of Health and Human Services, FDA. Development and Use of Risk Minimization Action Plans ( Risk- MAP Guidance). March 2005, Clinical Medical.
4Admad SR, Goetsch RA, Marks NS. Spontaneous Reporting in the United States [A]. in: Strom BL. Pharmacoepidemiology[ M]. Wiley,135-159.
5Burns W. WHO launches taskforce to fight counterfeit drugs [ J ]. Bulletin of the World Health Organization, 2006,84 (9) :6894590.
6Quick JD, Hogerzeil HV. Twenty-five years of essential medicines [ J ]. Bulletin of the World Health Organization, 2002, 80 (11) :913-914.
7Holloway K, Green T. Drug and Therapeutics Committees. A Practical Guide. Department of Essential Drugs and Medicines Policy. WHO 2003.
8IOM Report: More Bad News About Medication Errors[N]. The National Academics News,2006-09-14.
9WHO Policy Perspectives on Medicines-Pharmacovigilance: ensuring the safe use of medicines. Geneva, October, 2004.
10Department of Essential Drugs and Medicines Policy(EDM) :Safety of Medicines: A guide to detecting and reporting adverse drug reactions. World Health Organization,Geneva 2002.
5Kaushal R,Shojania KG,Bates DW. Effects of computer- ized physician order entry and clinical decision support systems on medication safety: asystematic review E J]. Arch Intern Med,2003,163(12) :1409 - 1416.
6High-Alert Medications and Patient Safety [J/OL]. Int J Qual Health Care ,2001,13(4) :339-340.
7Holland RW,Nimmo CM.Transitions in pharmacy practice, part 5: Walking the tightrope of change[J]. Am J Health-Syst Pharm, 2000,57(1):64-72.
8佚名.IsMP Medication saty self Assessment for Hospitals[EB/0L].http://www.ismp.or∥Survey/surveyresulfs/survey-Hospl.a8p.2011-12-22.
9Institute for Safe Medication Practices.ISMP's List of High-Alert Medications[EB/OL].[2012-12-01].http://www.ismp.org/Tools/highalertmedications.pdf.
10Suzarme G,Molly PC,Nicholas EK,et a1.Barbara crawfor Implementation of a high-alert medication program[]].The Permanente J,2008,12(2):15-22.
